Full Press Release Details
Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A.
BIIB
Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A
Key Takeaway: Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis